Banco Santander S.A. Grows Stock Position in Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Banco Santander S.A. has increased its stake in Bristol Myers Squibb Company by 19.1%, owning a total of 215,212 shares valued at approximately $13.13 million.
• Despite recent investment increases from various institutional investors, analysts have mixed ratings on Bristol Myers Squibb, with a consensus rating of "Hold" and an average price target of $57.33.
• Bristol Myers Squibb recently reported earnings of $1.46 per share, significantly beating estimates and indicating a net margin of 10.58% with revenues rising to $12.27 billion.

Banco Santander S.A. boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 19.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 215,212 shares of the biopharmaceutical company's stock after buying an additional 34,496 shares during the quarter. Banco Santander S.A.'s holdings in Bristol Myers Squibb were worth $13,126,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Thoroughbred Financial Services LLC grew its holdings in shares of Bristol Myers Squibb by 1.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 190 shares in the last quarter. Marcum Wealth LLC grew its holdings in shares of Bristol Myers Squibb by 1.0% during the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after buying an additional 193 shares in the last quarter. Beacon Investment Advisory Services Inc. grew its holdings in shares of Bristol Myers Squibb by 2.7% during the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock worth $492,000 after buying an additional 212 shares in the last quarter. 1858 Wealth Management LLC grew its holdings in shares of Bristol Myers Squibb by 3.6% during the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $392,000 after buying an additional 221 shares in the last quarter. Finally, Tompkins Financial Corp boosted its position in shares of Bristol Myers Squibb by 2.5% during the 1st quarter. Tompkins Financial Corp now owns 9,151 shares of the biopharmaceutical company's stock valued at $558,000 after acquiring an additional 225 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 2.6%

Shares of BMY stock traded up $1.16 during trading hours on Monday, reaching $45.39. 14,656,292 shares of the stock were exchanged, compared to its average volume of 13,625,376. The business's fifty day moving average is $47.51 and its two-hundred day moving average is $52.23. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The firm has a market capitalization of $92.39 billion, a P/E ratio of 18.30, a P/E/G ratio of 2.33 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the prior year, the firm earned $2.07 earnings per share. The business's quarterly revenue was up .6% compared to the same quarter last year. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.5%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BMY. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Finally, UBS Group lowered their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $57.33.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.